Parkinson disease (PD) is the most common movement disorder affecting over one million people in North America alone and results in an insidious reduction in the quality of life and ability to function. A hallmark of PD is the brain accumulation of neuronal cytoplasmic inclusions comprised of the protein alpha synuclein, but the presence of alpha synuclein brain aggregates is observed in a spectrum of neurodegenerative diseases, including dementia with Lewy body. Several findings suggest that alpha synuclein amyloid pathology may spread during disease progression by a self-templating alteration in protein conformation mechanism, however other alternative and/or synergistic biological mechanisms, as supported by our data, could also lead to progression of alpha synuclein pathology. From a therapeutic aspect it is critical to determine the relative importance, mechanisms and physiological consequences of the spread of alpha synuclein aggregation in disease. It this proposal, two major specific aims are proposed to inform on alpha synuclein induced and spread of disease: 1) Using both wild-type and disease causing mutant forms of alpha synuclein with unique aggregation properties, we will directly investigated that alpha synuclein aggregation can spread within the central nervous system and from the periphery with specific conformational characteristics. 2) We will assess the importance of alternative biological mechanisms including perturbation of the protein network homeostasis, neuronal intermediate filament integrity, neurotoxicity and age-related changes in the induction and propagation of alpha synuclein pathology by exogenous alpha synuclein challenges. These studies will provide critical insights on the mechanisms and the involvement of alpha synuclein aggregation in PD disease progression with the objective of guiding the development of novel therapeutics.
Parkinson disease is an insidious neurodegenerative disease, affecting ~1% of the population over 65 years of age. Progressive aggregation and inclusion formation of the protein alpha synuclein is a hallmark of this disorder and the planned research project focuses on understanding the underlying biological and molecular mechanisms involved in the development of disease with the objective of guiding novel therapeutic interventions.
|Uchihara, Toshiki; Giasson, Benoit I (2016) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 131:49-73|
|Sacino, Amanda N; Brooks, Mieu M; Chakrabarty, Paramita et al. (2016) Proteolysis of Î±-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. J Neurochem :|
|Sacino, Amanda N; Ayers, Jacob I; Brooks, Mieu M T et al. (2016) Non-prion-type transmission in A53T Î±-synuclein transgenic mice: a normal component of spinal homogenates from naÃ¯ve non-transgenic mice induces robust Î±-synuclein pathology. Acta Neuropathol 131:151-4|
|Rutherford, Nicola J; Brooks, Mieu; Giasson, Benoit I (2016) Novel antibodies to phosphorylated Î±-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes. Acta Neuropathol Commun 4:80|
|Rutherford, Nicola J; Sacino, Amanda N; Brooks, Mieu et al. (2015) Studies of lipopolysaccharide effects on the induction of Î±-synuclein pathology by exogenous fibrils in transgenic mice. Mol Neurodegener 10:32|
|Chakrabarty, Paramita; Hudson Iii, Vincent J; Sacino, Amanda N et al. (2015) Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission. Acta Neuropathol 130:303-5|
|Rutherford, Nicola J; Giasson, Benoit I (2015) The A53E Î±-synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture. Neurosci Lett 597:43-8|